Allergen Update

Dear Colleagues,

We are excited to announce newly released allergens from dog, egg, wheat, strawberry, kiwi and different tree nuts! Allergens are validated using Indoor Biotechnologies’ Mass Spectrometry (InBio® MS), ELISA, and IgE antibody binding. The allergens are manufactured under an ISO 9001:2015 certified Quality Management System.

Additionally, InBio® has a line of LoTox™ Food Source Materials, including hazelnut and peanut. Characteristics of the Food Source Materials include:

  • Prepared using standardized aseptic extraction conditions.
  • Specified low endotoxin levels (<0.03EU/µg protein).
  • Defined allergen composition validated by mass spectrometry or allergen-specific ELISA.
  •  
  • Allergen composition by mass spectrometry is measured as relative abundance of the predominant allergens, while the main allergen levels in the peanut food source material are quantified using individual peanut allergen-specific ELISA. The LoTox™ Food Source Materials have applications as reference standards for monitoring the composition of diagnostics and therapeutics or in research studies using human and murine cells.

Using its proven expertise in structural biology, protein expression and purification, Indoor Biotechnologies is proud to manufacture recombinant SARS-CoV-2 proteins including a full-length spike protein purified from mammalian cells (HEK). These proteins have been engineered, optimized and expressed in both mammalian and bacterial expression systems. InBio® SARS-CoV-2 proteins are validated for purity by LC-MS/MS, and IgG reactivity using COVID-19 patient sera by ELISA.

InBio® will be hosting a webinar on recombinant SARS-CoV-2 proteins and a rapid T cell assay. These products are essential tools for the assessment of SARS-CoV-2 specific humoral and cellular immune responses and can aid in COVID-19 research, diagnostics and vaccine efficiency testing. Please join us on Wednesday, October 27th, 2021 at 11am EDT. Details of the webinar and registration form (required) can be found here.

We hope that these new products will be useful for your research and product development. Please find product details and updates below.

Best wishes,
Sabina Wünschmann, PhD
Vice President, Allergen Manufacturing, R&D

New Allergens for Research and Diagnostic Use

InBio’s allergens are manufactured under an ISO 9001:2015 certified Quality Management System and validated using Mass Spectrometry, ELISA, and IgE antibody binding. Purified allergens have many applications, including molecular allergy diagnostics, allergen research, and as allergen standards. For more details on Indoor Biotechnologies’ full portfolio of over 100 purified allergens, see the Complete List of Allergens, visit our website, or contact Beattie Sturgill.

Allergen Pipeline

InBio’s scientists are continuously developing allergens. Please find table above for the allergen development pipeline. Indoor Biotechnologies also offers custom protein purifications. Please contact Beattie Sturgill to discuss your purification needs.

InBio® Allergen Value- What Sets Us Apart

Coronavirus Proteins for Research, Diagnostic Use, and Vaccine Development

InBio’s SARS-CoV-2 proteins are in stock, including a newly released full-length spike protein purified from mammalian cells (HEK).

The suite of SARS-CoV-2 proteins, include LoTox™ (low endotoxin, <0.03EU/µg protein) options which are ideal for T-cell and murine cellular studies. Viral proteins are expressed using mammalian and bacterial expression systems and purified via HPLC. Purity is assessed using Indoor Biotechnologies’ Mass Spectrometry (InBio® MS) and SDS-PAGE. SARS-CoV-2 proteins are validated by IgG antibody ELISA using serum samples from COVID-19 patients.

The SARS-CoV-2 recombinant proteins developed by InBio® will support diagnostic and therapeutic approaches, as well as research on the immune mechanisms involved in coronavirus infections. For further information about our SARS-CoV-2 proteins, please contact Dr.Sayeh Agah.

Silver-sained SDS-PAGE of SARS-CoV-2 Spike Protein Receptor Binding Domain (left) and the RNA-Binding Domain of the Nucleocapsid Protein (right)

Full-length Spike protein binding to human IgG antibodies using sera samples from COVID-19 patients.

InBio® Signs Distribution Agreement with MilliporeSigma

InBio is delighted to announce that it has entered into an agreement with Merck KGaA (Darmstadt, Germany), operating as MilliporeSigma in the US and Canada, to be a global distributor of Indoor Biotechnologies’ purified food allergens. The agreement signifies the increasing importance and relevance of food allergy research and diagnostics. Please find the press release for details.

The distribution agreement covers all geographies, and products will be stocked globally to improve availability to customers. Over 50 products from InBio®’s food allergen and protein portfolio can be found on MilliporeSigma’s website and will continue to be available through existing Indoor Biotechnologies channels, including www.inbio.com.

Want in? Subscribe to the InBio Newsletter stay up to date on all the latest innovations.